Search Results for: 58

— Company Focused on Prevention and Treatment of Serious Infectious Diseases — — Conference Call Scheduled for Wednesday, August 14, 2013, at 4:00 pm EDT — ROCKVILLE, Md., Aug. 8, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that […]

— Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets — ROCKVILLE, Md., April 16, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the year ended December 31, 2012 and summarized recent operational

— Accelerating Development of Product Candidates to Address Serious Infectious Diseases — ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, today reported financial results for the three and nine months ended September 30, 2012 and summarized operational highlights.

— Collaboration Harnesses Monoclonal Antibodies to Address Unmet Medical Needs — — Joint Conference Call Scheduled for Today, Wednesday, August 8, 2012 at 5:00pm(ET)/2:00pm(PT) — ROCKVILLE, Md. and SAN FRANCISCO, Aug. 8, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic biologics and innovative medicines for unmet medical needs, and Intrexon Corporation

— Company Prioritizes Focus on Synthetic DNA-Based Therapeutics — ANN ARBOR, Mich., March 30, 2012 /PRNewswire/ — Synthetic Biologics, Inc.  (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported  financial results for the year ended December 31, 2011 and summarized operational highlights. Operational Highlights Synthetic Biologics